A recent study published in the BIO Integration journal highlights the effectiveness of flurbiprofen ester in providing pain relief during transvaginal 4-dimensional hysterosalpingography (TVS 4D-HyCoSy). Conducted at a hospital between May 2018 and August 2021, the study involved 230 patients undergoing the procedure for infertility. Participants were divided into groups based on tubal patency, the use of flurbiprofen ester, and the diameter of the uterine cannula. The research focused on comparing the analgesic effects across these groups using visual analog scoring (NRS) for pain assessment while also documenting the incidence of adverse effects.
Findings revealed that tubal patency significantly decreased pain levels during the ultrasound examination. The use of flurbiprofen ester demonstrated substantial analgesic properties, effectively alleviating pain post-procedure and reducing adverse effects (P < 0.001). Notably, the diameter of the uterine cannula did not influence pain related to the tubal ultrasonography. Multivariable analysis indicated that flurbiprofen administration for patients with bilateral tubal patency resulted in considerable pain relief within 30 minutes after the examination, achieving an area under the curve (AUC) of 0.732 (95% CI: 0.665–0.798).
The study concludes that a continuous intravenous drip of flurbiprofen ester is effective for managing pain during TVS 4D-HyCoSy. The results emphasize the significance of flurbiprofen ester in improving patient comfort and reducing the likelihood of adverse reactions during the procedure, suggesting its potential for broader clinical application and promotion in obstetric and gynecological practices.
Read More
